Revolution Medicines, Inc. $RVMD Shares Bought by Checkpoint Capital L.P.

Checkpoint Capital L.P. lifted its position in Revolution Medicines, Inc. (NASDAQ:RVMD) by 75.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 492,300 shares of the company’s stock after acquiring an additional 212,300 shares during the period. Revolution Medicines comprises approximately 7.7% of Checkpoint Capital L.P.’s holdings, making the stock its 5th largest position. Checkpoint Capital L.P. owned approximately 0.25% of Revolution Medicines worth $22,990,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in the company. GAMMA Investing LLC boosted its stake in Revolution Medicines by 45.1% in the 3rd quarter. GAMMA Investing LLC now owns 837 shares of the company’s stock worth $39,000 after purchasing an additional 260 shares during the period. US Bancorp DE raised its stake in Revolution Medicines by 170.3% during the 3rd quarter. US Bancorp DE now owns 3,168 shares of the company’s stock valued at $148,000 after purchasing an additional 1,996 shares during the period. Osaic Holdings Inc. lifted its holdings in shares of Revolution Medicines by 41.7% in the second quarter. Osaic Holdings Inc. now owns 3,487 shares of the company’s stock valued at $128,000 after purchasing an additional 1,027 shares in the last quarter. Avanza Fonder AB lifted its holdings in shares of Revolution Medicines by 17.5% in the third quarter. Avanza Fonder AB now owns 4,335 shares of the company’s stock valued at $202,000 after purchasing an additional 647 shares in the last quarter. Finally, Arrowpoint Investment Partners Singapore Pte. Ltd. acquired a new stake in shares of Revolution Medicines in the third quarter worth $205,000. Institutional investors and hedge funds own 94.34% of the company’s stock.

Revolution Medicines Trading Down 0.2%

NASDAQ RVMD opened at $94.86 on Friday. Revolution Medicines, Inc. has a 1-year low of $29.17 and a 1-year high of $124.49. The company has a current ratio of 7.14, a quick ratio of 7.14 and a debt-to-equity ratio of 0.16. The company has a market capitalization of $18.80 billion, a PE ratio of -16.05 and a beta of 0.99. The firm’s fifty day simple moving average is $102.88 and its 200-day simple moving average is $74.97.

Revolution Medicines (NASDAQ:RVMD) last announced its quarterly earnings data on Wednesday, February 25th. The company reported ($1.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.56) by ($0.30). During the same period last year, the firm posted ($1.12) earnings per share. As a group, sell-side analysts anticipate that Revolution Medicines, Inc. will post -3.49 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently weighed in on RVMD. Benchmark reiterated an “overweight” rating on shares of Revolution Medicines in a report on Tuesday, February 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of Revolution Medicines in a research note on Thursday, January 22nd. Evercore upgraded Revolution Medicines to a “strong-buy” rating in a research report on Wednesday, February 25th. Wedbush reaffirmed an “outperform” rating on shares of Revolution Medicines in a research note on Friday, January 9th. Finally, UBS Group assumed coverage on Revolution Medicines in a report on Friday, February 27th. They issued a “buy” rating on the stock. Four investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $78.94.

Insider Transactions at Revolution Medicines

In related news, insider Mark A. Goldsmith sold 6,000 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $101.30, for a total value of $607,800.00. Following the completion of the sale, the insider owned 64,424 shares of the company’s stock, valued at approximately $6,526,151.20. The trade was a 8.52% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Stephen Michael Kelsey sold 5,447 shares of the stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $76.82, for a total value of $418,438.54. Following the completion of the transaction, the insider owned 278,600 shares in the company, valued at $21,402,052. This represents a 1.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 149,792 shares of company stock valued at $14,379,040 over the last 90 days. Company insiders own 8.20% of the company’s stock.

Revolution Medicines Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.